Meridian Bioscience Company Profile (NASDAQ:VIVO)

About Meridian Bioscience (NASDAQ:VIVO)

Meridian Bioscience logoMeridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:VIVO
  • CUSIP: 58958410
  • Web:
  • Market Cap: $584.5 million
  • Outstanding Shares: 42,202,000
Average Prices:
  • 50 Day Moving Avg: $14.10
  • 200 Day Moving Avg: $14.96
  • 52 Week Range: $10.75 - $20.68
  • Trailing P/E Ratio: 19.53
  • Foreward P/E Ratio: 19.79
  • P/E Growth: 1.18
Sales & Book Value:
  • Annual Revenue: $198.6 million
  • Price / Sales: 2.94
  • Book Value: $4.05 per share
  • Price / Book: 3.42
  • Annual Dividend: $0.50
  • Dividend Yield: 3.7%
  • EBIDTA: $55.72 million
  • Net Margins: 15.13%
  • Return on Equity: 18.51%
  • Return on Assets: 12.23%
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 5.99%
  • Quick Ratio: 3.87%
  • Average Volume: 336,182 shs.
  • Beta: 1
  • Short Ratio: 8.34

Frequently Asked Questions for Meridian Bioscience (NASDAQ:VIVO)

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?

Meridian Bioscience announced a quarterly dividend on Thursday, April 27th. Shareholders of record on Monday, May 8th will be paid a dividend of $0.125 per share on Thursday, May 18th. This represents a $0.50 annualized dividend and a yield of 3.61%. The ex-dividend date is Thursday, May 4th. View Meridian Bioscience's Dividend History.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its quarterly earnings results on Friday, April, 28th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.03. The firm had revenue of $54.13 million for the quarter, compared to the consensus estimate of $51.16 million. Meridian Bioscience had a return on equity of 18.51% and a net margin of 15.13%. Meridian Bioscience's revenue for the quarter was up 5.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.24 EPS. View Meridian Bioscience's Earnings History.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience issued an update on its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $0.64-0.69 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.66. The company issued revenue guidance of $193-199 million, compared to the consensus revenue estimate of $194.58 million.

Where is Meridian Bioscience's stock going? Where will Meridian Bioscience's stock price be in 2017?

5 brokerages have issued twelve-month price targets for Meridian Bioscience's stock. Their forecasts range from $9.00 to $19.00. On average, they anticipate Meridian Bioscience's share price to reach $14.33 in the next twelve months. View Analyst Ratings for Meridian Bioscience.

Who are some of Meridian Bioscience's key competitors?

Who owns Meridian Bioscience stock?

Meridian Bioscience's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Brown Capital Management LLC (13.47%), Vanguard Group Inc. (8.73%), Renaissance Technologies LLC (4.71%), Dimensional Fund Advisors LP (3.38%), State Street Corp (2.95%) and BTIM Corp. (2.22%). Company insiders that own Meridian Bioscience stock include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.

Who sold Meridian Bioscience stock? Who is selling Meridian Bioscience stock?

Meridian Bioscience's stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Capstone Asset Management Co., Martingale Asset Management L P, Morgan Stanley, BTIM Corp., Schwab Charles Investment Management Inc., Menta Capital LLC and Nationwide Fund Advisors. Company insiders that have sold Meridian Bioscience stock in the last year include Richard Eberly and Vecheslav A Elagin. View Insider Buying and Selling for Meridian Bioscience.

Who bought Meridian Bioscience stock? Who is buying Meridian Bioscience stock?

Meridian Bioscience's stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Clark Estates Inc. NY, FMR LLC, State Street Corp, Quadrant Capital Group LLC, Dean Investment Associates LLC, Kennedy Capital Management Inc. and Renaissance Technologies LLC. Company insiders that have bought Meridian Bioscience stock in the last two years include Catherine Sazdanoff, Dwight E Ellingwood, John A Kraeutler, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.

How do I buy Meridian Bioscience stock?

Shares of Meridian Bioscience can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Meridian Bioscience stock cost?

One share of Meridian Bioscience stock can currently be purchased for approximately $13.85.

Analyst Ratings

Consensus Ratings for Meridian Bioscience (NASDAQ:VIVO) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings
Consensus Rating:Hold (Score: 1.80)
Consensus Price Target: $14.33 (3.49% upside)

Analysts' Ratings History for Meridian Bioscience (NASDAQ:VIVO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017Canaccord GenuityBoost Price TargetHold$13.00 -> $15.00LowView Rating Details
3/28/2017CL KingInitiated CoverageNeutral -> NeutralHighView Rating Details
1/31/2017Craig HallumDowngradeBuy -> HoldN/AView Rating Details
1/25/2017Piper Jaffray CompaniesSet Price TargetSell$9.00N/AView Rating Details
7/29/2016Hilliard LyonsDowngradeBuy -> HoldN/AView Rating Details
3/29/2016Robert W. BairdReiterated RatingHold$20.00N/AView Rating Details
1/27/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Meridian Bioscience (NASDAQ:VIVO)
Earnings by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Earnings History by Quarter for Meridian Bioscience (NASDAQ:VIVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/2017Q2 2017$0.19$0.22$51.16 million$54.13 millionViewN/AView Earnings Details
1/25/2017Q1 2017$0.20$0.15$51.15 million$46.80 millionViewN/AView Earnings Details
11/10/2016Q4 2016$0.14$0.14$47.17 million$47.00 millionViewN/AView Earnings Details
7/28/2016Q3$0.22$0.21$52.85 million$50.70 millionViewN/AView Earnings Details
4/28/2016Q2$0.24$0.24$52.10 million$51.30 millionViewN/AView Earnings Details
1/27/2016Q1$0.21$0.21$48.60 million$47.20 millionViewN/AView Earnings Details
11/5/2015Q4$0.21$0.20$45.70 million$47.10 millionViewN/AView Earnings Details
7/23/2015Q3$0.22$0.22$48.60 million$48.20 millionViewN/AView Earnings Details
4/23/2015Q115$0.24$0.24$50.50 million$51.55 millionViewN/AView Earnings Details
1/22/2015Q414$0.19$0.19$46.20 million$48.00 millionViewN/AView Earnings Details
11/6/2014Q4$0.22$0.20$48.94 million$46.70 millionViewN/AView Earnings Details
7/24/2014Q3$0.22$0.21$47.96 million$47.20 millionViewN/AView Earnings Details
4/24/2014Q214$0.27$0.24$52.18 million$50.13 millionViewN/AView Earnings Details
1/22/2014Q114$0.18$0.18$47.59 million$44.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.23$0.22$49.24 million$48.96 millionViewN/AView Earnings Details
7/25/2013Q3 2013$0.21$0.24$47.00 million$47.10 millionViewN/AView Earnings Details
4/25/2013Q2 2013$0.24$0.24$49.66 million$47.26 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.19$0.20$44.34 million$45.40 millionViewN/AView Earnings Details
11/8/2012Q412$0.19$0.21$43.22 million$43.70 millionViewN/AView Earnings Details
7/26/2012$0.22$0.21ViewN/AView Earnings Details
4/26/2012$0.21$0.23ViewN/AView Earnings Details
1/25/2012$0.19$0.17ViewN/AView Earnings Details
11/10/2011$0.19$0.18ViewN/AView Earnings Details
7/21/2011$0.21$0.17ViewN/AView Earnings Details
4/21/2011$0.20$0.20ViewN/AView Earnings Details
1/20/2011$0.19$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Meridian Bioscience (NASDAQ:VIVO)
2017 EPS Consensus Estimate: $0.81
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.17$0.17$0.17
Q2 20171$0.22$0.22$0.22
Q3 20171$0.22$0.22$0.22
Q4 20171$0.20$0.20$0.20
(Data provided by Zacks Investment Research)


Current Dividend Information for Meridian Bioscience (NASDAQ:VIVO)
Most Recent Dividend:5/18/2017
Annual Dividend:$0.50
Dividend Yield:3.61%
Payout Ratio:71.43% (Trailing 12 Months of Earnings)
73.53% (Based on This Year's Estimates)
71.43% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Dividend History by Quarter for Meridian Bioscience (NASDAQ:VIVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Meridian Bioscience (NASDAQ:VIVO)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 87.90%
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Insider Trades by Quarter for Meridian Bioscience (NASDAQ:VIVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/2/2017Melissa LuekeCFOBuy4,000$12.59$50,360.00View SEC Filing  
1/26/2017Lawrence BaldiniEVPBuy4,000$12.70$50,800.00View SEC Filing  
12/2/2016Vecheslav A ElaginEVPSell7,883$17.30$136,375.90View SEC Filing  
11/30/2016Dwight E EllingwoodDirectorBuy1,020$17.12$17,462.40View SEC Filing  
11/16/2016Richard EberlyEVPSell4,926$17.00$83,742.00View SEC Filing  
11/4/2016John A KraeutlerChairmanBuy5,000$16.13$80,650.00View SEC Filing  
11/3/2016Lawrence BaldiniEVPBuy4,900$16.00$78,400.00View SEC Filing  
8/11/2016John McilwraithDirectorBuy1,000$19.57$19,570.00View SEC Filing  
4/29/2016Catherine SazdanoffDirectorBuy7,700$19.20$147,840.00View SEC Filing  
12/9/2015Vecheslav A ElaginEVPSell7,500$19.75$148,125.00View SEC Filing  
12/1/2015Richard EberlyEVPSell4,934$19.61$96,755.74View SEC Filing  
3/2/2015Marviette D JohnsonVPSell1,917$19.91$38,167.47View SEC Filing  
1/23/2015Dwight E EllingwoodDirectorBuy1,980$17.74$35,125.20View SEC Filing  
12/1/2014Susan RolihEVPSell11,219$16.46$184,664.74View SEC Filing  
11/21/2014Dwight E EllingwoodDirectorBuy1,000$16.08$16,080.00View SEC Filing  
11/18/2014John A KraeutlerCEOSell10,500$16.20$170,100.00View SEC Filing  
11/18/2014Melissa LuekeCFOSell6,713$16.20$108,750.60View SEC Filing  
11/11/2014David PhillipsDirectorBuy10,000$16.89$168,900.00View SEC Filing  
6/13/2014Robert J ReadyDirectorSell2,700$20.03$54,081.00View SEC Filing  
12/5/2013Vecheslav ElaginEVPSell4,141$23.74$98,307.34View SEC Filing  
11/22/2013Susan RolihEVPSell9,086$24.18$219,699.48View SEC Filing  
11/21/2013Richard EberlyEVPSell4,926$24.50$120,687.00View SEC Filing  
11/19/2013Lawrence BaldiniVPSell4,926$24.26$119,504.76View SEC Filing  
11/11/2013John KraeutlerCEOSell5,250$25.27$132,667.50View SEC Filing  
7/26/2013Lawrence BaldiniVPSell32,000$24.14$772,480.00View SEC Filing  
5/1/2013John A KraeutlerCEOBuy5,000$19.63$98,150.00View SEC Filing  
12/3/2012Lawrence BaldiniVPSell32,500$20.00$650,000.00View SEC Filing  
11/13/2012Robert J ReadyDirectorSell1,800$19.46$35,028.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Meridian Bioscience (NASDAQ:VIVO)
Latest Headlines for Meridian Bioscience (NASDAQ:VIVO)
DateHeadline logoMeridian Bioscience (VIVO) Presents At UBS Global Healthcare Conference 2017 - Slideshow - May 24 at 8:23 AM logoRobbins Arroyo LLP Is Investigating the Officers and Directors of Meridian Bioscience, Inc. (VIVO) on Behalf of Shareholders - May 22 at 7:35 PM logoETFs with exposure to Meridian Bioscience, Inc. : May 19, 2017 - May 19 at 6:37 PM logo​FDA says Billerica firm’s lead tests may be faulty in some cases - May 19 at 1:36 PM logoUPDATE 3-U.S. health officials warn of problems with Meridian lead tests - May 19 at 1:36 PM logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : May 18, 2017 - May 18 at 10:46 AM logoMeridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2017 By the Numbers : May 18, 2017 - May 18 at 10:46 AM logoMeridian Bioscience (VIVO) Comments on FDA Matter for Subsidiary, Magellan Diagnostics - May 17 at 9:44 PM logoMeridian Bioscience Comments on FDA Matter Involving its Subsidiary, Magellan Diagnostics - May 17 at 9:44 PM logoTests for lead poisoning may be faulty, US regulators warn - May 17 at 6:43 PM logoMeridian Bioscience stock plummets after FDA warns subsidiary's lead tests may be inaccurate - May 17 at 10:29 AM logoMeridian Bioscience, Inc. (VIVO) Expected to Post Quarterly Sales of $49.41 Million - May 13 at 8:58 AM logoZacks: Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Post $0.16 EPS - May 11 at 10:42 AM logoOne of Cincinnati's largest public companies launches CEO search - May 11 at 3:12 AM logoMeridian Bioscience, Inc. (VIVO) Upgraded at Zacks Investment Research - May 10 at 10:36 PM logoMeridian Bioscience (VIVO) Begins CEO Search as John A. Kraeutler Announces Plans to Retire - May 10 at 9:57 AM logoMeridian Bioscience Engages Korn Ferry to Conduct CEO Search as John A. Kraeutler Announces Plans to Retire - May 10 at 9:57 AM logoMagellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Launches National Education Initiative on Risks of Lead Exposure for Pregnant Women - May 9 at 9:45 AM logoMeridian Continues Its Fight Against Tropical Diseases by Introducing the Most Comprehensive Menu of Antigens and Antibodies for Diagnostic Applications - May 5 at 3:19 AM logoSomewhat Positive News Coverage Likely to Affect Meridian Bioscience (VIVO) Stock Price - May 4 at 4:46 PM logoCanaccord Genuity Reiterates "Hold" Rating for Meridian Bioscience, Inc. (VIVO) - May 3 at 1:33 PM logoMeridian Bioscience (VIVO) Getting Somewhat Critical Media Coverage, AlphaOne Reports - May 1 at 3:50 PM logoBrokers Set Expectations for Meridian Bioscience, Inc.'s FY2018 Earnings (VIVO) - May 1 at 1:06 PM logoMeridian Bioscience, Inc. (VIVO) Receives Average Recommendation of "Hold" from Brokerages - May 1 at 12:56 PM logoMeridian Bioscience, Inc. (VIVO) Lifted to Hold at Zacks Investment Research - April 29 at 7:30 AM logoSomewhat Positive Press Coverage Extremely Likely to Affect Meridian Bioscience (VIVO) Share Price - April 28 at 2:28 PM logoMeridian Bioscience Q2 Results Beat View; Reiterates FY17 Outlook - April 27 at 11:01 PM logoMeridian Bioscience, Inc. (VIVO) Announces $0.13 Quarterly Dividend - April 27 at 8:16 PM logoMeridian Bioscience, Inc. (VIVO) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS - April 27 at 3:16 PM logoMeridian Bioscience, Inc. (VIVO) Releases FY17 Earnings Guidance - April 27 at 10:36 AM logoMeridian Bioscience beats 2Q profit forecasts - April 27 at 9:34 AM logoMarkets open higher, Street eyes earnings and Trump tax plan - Presented by: The Aol. On Network - April 26 at 5:06 PM logoMeridian Bioscience Inc. (Nasdaq: VIVO) to Ring The Nasdaq Stock Market Opening Bell - April 26 at 5:06 PM logoMeridian Bioscience (VIVO) Receives News Impact Rating of -0.20 - April 25 at 12:04 PM logoMeridian Bioscience, Inc.: New Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria - April 25 at 8:49 AM logoNew Testing Procedure Holds Promise As a Critical Tool in the Global Effort to Eliminate Malaria - April 24 at 9:17 AM logoSomewhat Favorable News Coverage Likely to Impact Meridian Bioscience (VIVO) Stock Price - April 20 at 7:45 PM logoZacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.19 Per Share - April 20 at 2:58 PM logoMeridian Bioscience, Inc.: ECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection - April 18 at 7:40 PM logoMeridian Bioscience (VIVO) Earning Somewhat Positive News Coverage, AlphaOne Reports - April 17 at 10:53 AM logoECCMID Presentation to Demonstrate Revolutionary Breakthrough in Malaria Detection - April 17 at 8:19 AM logoMeridian Bioscience, Inc. (VIVO) Receives New Coverage from Analysts at CL King - April 3 at 12:34 PM logoMeridian Bioscience, Inc. Expects to Report Second Quarter Fiscal 2017 Operating Results on Thursday, April 27, 2017 - March 29 at 10:35 AM logoCoverage initiated on Meridian Bioscience by CL King - March 28 at 10:32 PM logoBioline Launches New JetSeq DNA Quantification Kits - March 27 at 7:49 PM logoMagellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs Exclusive Partnership to Provide Portable Blood Lead Testing in Africa - March 7 at 8:53 PM logoMERIDIAN BIOSCIENCE INC Financials - February 17 at 6:14 AM logoMERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report - February 10 at 6:29 AM logoBioline Launches New JetSeq™ DNA Library Preparation Kits - February 9 at 6:32 AM logoBioline Launches New JetSeq(TM) DNA Library Preparation Kits - February 9 at 6:32 AM



Meridian Bioscience (VIVO) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff